Answers are grounded in this paper and cite their sources.
Though continuous glucose monitoring systems (CGMS) have proven their benefits in type 1 diabetes mellitus, research about their use in type 2 diabetes mellitus (Τ2D) are still in progress.The current study aimed to evaluate the use of such systems in patients with T2D in comparison with the standard periodic capillary measurements.Twenty-five patients with T2D under insulin or combination of insulin and oral medication participated in a prospective 7-day observational study.American Diabetes Association 2021 targets for good euglycemic control were used as primary goals for the two groups (CGMS over capillary measurements).Seventy two percent of the participant achieved maintenance of blood glucose within therapy target guidelines.Moreover, 64 % of the participants achieved glycohemoglobin HbA1c < 6.5 %.Glucose values with both methods display high level of correlation ((r = 0.901, p < 0.001) and the same is also valid for HbA1c and estimated HbA1c ((r = 0.939, p < 0.001).Thus, CGMS can achieve both better glycemic control and decrease of HbA1c in patients with T2D.Though the present findings are in accordance with the available literature, further studies in larger populations with more deeper analyses are still needed to confirm the usefulness of CGMS in T2D.
No takes yet. Share an insight, caveat, or question.
A 2022 study studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: